Wedbush raised the firm’s price target on Kiniksa (KNSA) to $44 from $38 and keeps an Outperform rating on the shares. The firm says the company heads into Q3 earnings on the heels of another strong quarter that further reinforced Arcalyst’s durable growth trajectory in recurrent pericarditis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KNSA: